Cardiotoxicity in breast cancer patients: A single center, retrospective review

While advances in breast cancer treatment, including targeted therapies, have improved patient outcomes, such treatments may be associated with both short and long term toxicity. In 2008, The Ottawa Hospital cardiac oncology clinic was established with the goal of providing timely access and care to cancer patients experiencing cancer therapy-related cardiotoxicity. 263 breast cancer patients referred to the cardiac oncology clinic between October 2008 and January 2013 were reviewed. Data included: age, sex, date of diagnosis, date of referral to cardiac oncology clinic, stage of breast cancer at diagnosis and referral, cardiac history, medications, cancer therapy, treatment delays and completion rates, cardiac complications, cardiac test results and interventions. Descriptive statistical analysis was performed. The most common reason for referral was for drop in left ventricular ejection fraction during treatment with trastuzumab. While the majority of breast cancer patients were able to complete cancer therapy, a significant proportion experienced cardiotoxicity leading to delay or discontinuation of treatment. Tools to identify patients at higher risk of developing cardiotoxicity are urgently needed so that appropriate monitoring and treatment can be initiated. Future studies will determine the impact of this clinic on the delivery of cancer therapy and cardiac health.

Duke Scholars

Author Susan Faye Dent Medicine, Medical Oncology